Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA reverses stance and expands access to Plan B

This article was originally published in Scrip

Executive Summary

The US FDA will clear the way for women as young as 17 years of age to have access to Barr Pharmaceuticals' (now Teva Pharmaceutical Industries) emergency contraceptive Plan B (levonorgestrel) over the counter. The product is currently available without a prescription to women aged 18 years and older, although it is sold behind pharmacy counters. Younger women need a prescription.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts